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Abstract
The lysyl-tRNA synthetase paralog PoxA modifies elongation factor P (EF-P) with α-lysine at low 
efficiency. Cell-free extracts contained non-α-lysine substrates of PoxA that modified EF-P by a 
change in mass consistent with β–lysine, a substrate also predicted by genomic analyses. EF-P was 
efficiently, functionally, modified with (R)-β-lysine but not (S)-β-lysine or genetically encoded α-
amino acids, indicating that PoxA has evolved an activity orthogonal to that of the canonical 
aminoacyl-tRNA synthetases.
The aminoacyl-tRNA synthetases family (aaRSs) encompasses 20 canonical enzymes that 
match amino acids with their corresponding tRNAs during translation1. The aaRSs are 
divided between classes I and II, each of which is characterized by a core catalytic domain 
responsible for ATP-dependent acyl-adenylate synthesis2. These core domains recognize 
and activate specific amino acids, which are transferred to the 3' end of tRNA. AaRSs are 
highly modular and contain domains appended to the catalytic core that assist in RNA 
binding and recognition, and in proofreading of incorrect aminoacylation products3. In 
addition to the canonical enzymes required for translation, the aaRS superfamily contains 
paralogs that recapitulate either the core or the appended domains of aaRSs4. AaRS paralogs 
generally retain some degree of specificity for canonical protein synthesis substrates, amino 
acid or tRNA, whether or not they function inside or outside translation5. One notable 
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exception is PoxA, a paralog of lysyl-tRNA synthetase (LysRS), which does not recognize 
tRNA but instead post-translationally modifies elongation factor P (EF-P), a protein that 
mimics tRNA in both shape and size6–8. EF-P modification leads to specific alterations in 
the proteome and is required for virulence in Salmonella, but exactly how PoxA modifies 
EF-P to elicit these changes is unknown7.
Structural studies suggest PoxA recognizes EF-P in a similar manner to that by which 
LysRS binds tRNALys 7,8. Aminoacylation assays show the KM of PoxA for EF-P (3.2 µM) 
is similar to values determined for bacterial class II-type LysRS with tRNALys (1–2 µM9,10). 
PoxA cannot aminoacylate tRNALys, indicating that while it is structurally similar to LysRS 
its activity is different from that of a canonical aaRS11. The amino acid binding pockets of 
PoxA and LysRS also appear highly similar and super positioning of the α-carbons within 
the active sites shows an RMSD of 1.1 Å (Fig. 1a). Using the LysRS co-crystal structure, 
lysyl-adenylate can be docked into the active site of PoxA, consistent with previous findings 
that lysine is a substrate for EF-P modification in vitro7. While lysine was a substrate for 
PoxA, the reaction was extremely inefficient compared to amino acid activation by LysRS 
(Supplementary Methods, Table 1). Characterization of amino acid activation by PoxA 
under a variety of conditions did not lead to significant improvements in the efficiency of 
the reaction (Supplementary Results, Supplementary Fig. 1), suggesting that lysine may not 
be the cognate substrate. This was supported by comparing the PoxA and LysRS active 
sites, which indicated divergence of two conserved residues predicted to impact substrate 
specificity, Ser76 and Ala294 (Fig. 1a; Escherichia coli PoxA numbering). The effect of 
reverting these PoxA residues to their conserved LysRS identities was investigated by 
comparing the apparent amino acid binding affinities of the S76A and A294G variants to 
wild-type. The S76A mutation abolished all activity, while A294G showed a 25-fold 
decrease in the KM for lysine compared to wild-type (Table 1). These data indicate PoxA is 
not optimized to use lysine as its preferred substrate, but has instead evolved amino acid 
specificity divergent from that of LysRS.
Previous studies show different LysRSs preferentially recognize particular non-cognate 
amino acids12, and the specificity of PoxA was similarly tested (Fig. 1b). PoxA did not 
activate either other non-cognate genetically encoded amino acids or various commercially 
available analogs more efficiently than lysine. This raised the possibility that another amino 
acid was the preferred substrate of PoxA in vivo. E. coli cell-free extracts showed 
significantly higher stimulation of ATP / PPi exchange activity than expected based solely 
upon their lysine content, suggesting the presence of a second, more efficient, substrate 
(Supplementary Fig. 2a). Cell-free extracts were fractionated and the resulting samples 
tested for ATP / PPi exchange activity using LysRS and PoxA (Supplementary Fig. 2b). 
Optimal activities for LysRS and PoxA did not co-fractionate during purification, supporting 
the idea that E. coli cell-free extracts contained a substrate for EF-P modification distinct 
from lysine (Fig. 1c). The identity of the amino acid attached by PoxA in vivo was 
investigated by mass spectroscopy of both affinity purified EF-P, and of EF-P modified in 
vitro using enriched cell-free extracts. In both cases EF-P was site-specifically modified at 
Lys34 by a mass consistent with the attachment of lysine (Supplementary Fig. 3). These data 
showed that while the genetically encoded amino acid α-lysine was not the optimal substrate 
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for PoxA, EF-P is nevertheless modified by a compound with the mass of lysine, consistent 
with previous reports8,13.
Genomic and phylogenetic studies predict that β-lysine might be the natural substrate for 
PoxA6,7, consistent with the mass observed for modified EF-P and with the detection in vivo 
of a substrate distinct from α-lysine. (R)-β-lysine was 100-fold more efficient as a substrate 
than either (S)-β-lysine or α-lysine (Fig. 2a), suggesting that (R)-β-lysine is the cognate 
substrate for EF-P modification (Table 1). In contrast, (R)-β-lysine was a poor substrate 
compared to α-lysine for LysRS (Supplementary Fig. 4a) indicating that the amino acid 
substrate specificity of PoxA is different to that of the ancestral aaRS from which it evolved. 
The ability of PoxA to post-translationally modify EF-P with β-lysine was examined in vitro 
and found to be considerably more efficient than modification with α-lysine (Fig. 2b). β-
lysine was also a potent inhibitor of α-lysine modification of EF-P, consistent with this 
reaction being orthogonal to tRNA aminoacylation by LysRS (Supplementary Fig. 4b).
Previous studies established that EF-P, PoxA and the 2,3-β-lysine aminomutase encoded by 
yjeK8,14 act together in vivo to establish virulence in Salmonella, and are important for 
maintenance of stress resistance phenotypes including resistance to gentamicin and growth 
on AB2 media7,15. The latter phenotype was used to assess how modification with β-lysine 
affects the functional activity of EF-P in vivo. Complementation of a poxA yjeK double 
knockout strain showed that neither wild-type PoxA nor the A298G variant could restore 
normal growth on AB2 media, suggesting that lysylation alone (as opposed to β-lysylation) 
is not sufficient to create functional EF-P (Supplementary Fig. 5). To more directly 
investigate the role of β-lysylation of EF-P in vivo, we attempted to restore the growth of the 
yjeK mutant on gentamicin by supplementation with different forms of lysine. β-lysine, but 
not α-lysine, was able to restore growth of the yjeK mutant in the presence of gentamicin 
(Fig. 2c). These data show that functional EF-P is dependent on post-translational 
modification by PoxA specifically with β-lysine, and that synthesis of β-lysine by YjeK 
occurs prior to addition rather than by a post-addition rearrangement of α-lysine.
Perturbation of the post-translational modification of EF-P by PoxA gives rise to changes in 
translation that attenuate Salmonella virulence7,15,16. The chemical nature of this novel 
modification is a critical determinant of EF-P activity; while both α- and β-lysine are 
substrates for PoxA, only the latter amino acid generates the biologically active form of EF-
P. What remains unclear is how attachment of β-lysine changes the activity of EF-P. One 
possibility is that β-lysine acts as a recognition element for ribosome binding, although this 
may not be a universal role as unmodified isoforms of EF-P can also bind to bacterial 
ribosomes17 and a number of bacteria encode EF-P but not PoxA or YjeK6. Comparisons to 
the eukaryotic homolog eIF5a18 suggest that addition of β-lysine may contribute to the 
ability of EF-P to promote translation initiation and /or elongation13,19. The modification of 
eIF5a with hypusine, by an unrelated pathway, is required for its stimulatory effect on 
translation20, and the availability of a defined in vitro modification system will now allow 
similar effects to be tested for with EF-P. The availability of a defined modification system 
in vivo will in addition facilitate investigation of the proposal that EF-P stimulates 
translation of specific messages7,16, a role also proposed for eIF5a but for which there is no 
known mechanism18.
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Post-translational modification of EF-P is based on molecular mimicry of a pathway 
hijacked from the translation machinery. To achieve the substrate specificity necessary to 
modify EF-P with β-lysine, PoxA evolved two specificities orthogonal to those of the 
protein from which it is derived, the class II-type LysRS. Elimination of the amino-terminal 
anticodon-binding domain of LysRS would have substantially reduced affinity for tRNA10, 
and allowed PoxA to evolve the protein-protein interactions that permit it to specifically 
recognize the tRNA-mimic EF-P8 but not tRNALys. The evolution of amino acid specificity 
in PoxA appears to have been primarily driven by selection for β-lysine as a substrate, and 
may have been facilitated by the lack of selection to maintain a high turnover rate. The 
biological role of LysRS, providing Lys-tRNALys for protein synthesis, requires a high rate 
of product synthesis whereas PoxA would be required to have a far lower turnover rate. As a 
result, only very few active site replacements compared to LysRS are sufficient to provide 
PoxA with useful β-lysine specificity, since any accompanying loss in turnover number is 
still compatible with a biologically relevant rate of EF-P modification.
Many aaRS paralogs have been sequenced and annotated, but to date functions have only 
been assigned to a small fraction4,21,22. The relative ease with which PoxA apparently 
acquired new substrate specificities suggests that alternative mechanisms of post-
translational modification, and amino acid-dependent transformations, may be associated 
with other aaRS paralogs. The substrate specificity of PoxA also opens up the possibility 
that aaRS paralogs could provide the basis for new tools for protein design and engineering. 
The orthogonality of PoxA to the translation machinery mirrors that of systems developed 
for co-translational insertion of unnatural amino acids23, suggesting that similar approaches 
could be developed in the future to evolve new post-translational protein modification 
activities.
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Figure 1. Amino acid recognition by PoxA
(a) The 20 amino acids forming the lysyl-adenylate binding pocket of PoxA and LysRS are 
identical, apart from the two positions indicated in red. For clarity, only 14 residues are 
represented. Crystal structures are LysRS from Bacillus stearothermophilus24 and PoxA 
from Salmonella enterica Typhimurium7. The Van der Waals surface of the lysyl-adenylate 
is represented. S. enterica Ala298 corresponds to E. coli Ala294. (b) PoxA-catalyzed 
ATP/PPi exchange in the presence of non-cognate amino acids (single letter code) and 
lysine analogs. The concentration of each amino acid was 20 mM. Errors correspond to the 
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standard deviation from three independent experiments. (c) Metabolite fractionation by LC 
on silica gel. Fractions were separately tested for stimulation of ATP/PPi exchange 
catalyzed by PoxA (○) or LysRS (□).
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Figure 2. Modification of EF-P with β-lysine
(a) Lysine structures (b) PoxA catalyzed aminoacylation of EF-P with (R)-β-lysine. 
Aminoacylation of EF-P or the inactive K34A variant was assayed in the presence or 
absence of 20µM (R)-β-lysine, (S)-β-lysine, or α-lysine. Modified EF-P containing an 
additional –NH3+ group was separated from the unmodified EF-P by 1D isoelectric focusing 
and detected by western blotting. (c) Complementation of Salmonella ΔyjeK strain with (R)-
β-lysine. Growth in liquid LB with (+) or without (−) 8 µg/ml gentamicin for 24 hours at 37 
°C. Growth was monitored in the presence of either 0.8 mM (R)-β-lysine, 0.8 mM α-lysine, 
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or no lysine (−). Optical densities of replicate cultures are plotted. Growth rates were 
consistently slower on β-lysine than on α-lysine, suggesting a modest inhibitory effect at the 
concentrations used, the reason for which is presently unclear.
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Table 1
Steady-state kinetics of amino acid activation by E. coli LysRS and PoxA.
KM (µM) kcat (min−1) kcat / KM (min−1µM−1)
L-α-lysine
LysRS1 43 3000 70
PoxA 8600 ± 1200 15 ± 1.3 17 × 10−4
PoxA A294G 344 ± 44 3.8 ± 0.6 111 × 10−4
(R)-β-lysine
PoxA 213 ± 31 36 ± 3.3 1690 ×10 −4
PoxA A294G 414 ± 63 17 ± 0.5 410 × 10−4
(S)-β-lysine
PoxA 6950 ± 1894 2.8 ± 0 4 × 10−4
1
Values previously determined for the lysS-encoded protein25. Errors correspond to the standard deviation from three independent experiments.
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